Psyence Group Corporate Update
Highlights: Drug development, Phase IIb clinical trial advanced planning underway in AustraliaPsyence granted worldwide licensing agreement to commercialize Filament’s PEX010...
Neurology
Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
WALTHAM, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing...
Salix Announces 2023 Gastrointestinal Health Scholars Program Winners
For Fourth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 ScholarshipLAVAL, QC / ACCESSWIRE / July...
Salix Announces 2023 Gastrointestinal Health Scholars Program Winners
For Fourth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 ScholarshipLAVAL, QC / ACCESSWIRE / July...
Psyence Appoints Intellectual Property Expert to Its Board of Directors
TORONTO, July 11, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is...
Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership
EVOTEC AND BRISTOL MYERS SQUIBB ENTER EXCLUSIVE GLOBAL LICENCE AGREEMENT FOR SELECTED PROGRAMMES DEVELOPED AND PROGRESSED IN THE COLLABORATIONSELECTED PROGRAMMES...
Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury
New data in traumatic brain injury (TBI) builds on prior study in insomnia, which has been shown to have high correlation...
Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer
CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers...
BioVie to Present Data Showing How NE3107 Potentially Regulates DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease
CARSON CITY, Nev., July 10, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company...
FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
The first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional...
Assure Holdings Expands Service Offerings to Address the High Growth EEG Services Market
Signs Diagnostics Services Agreement with Neurovative DiagnosticsDENVER, June 27, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”)...
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in the European Union for Adults with Late-onset Pompe Disease (LOPD)PHILADELPHIA, June...
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease Ongoing Phase 1b/2 ABATE...
Assure Holdings Signs Letter of Intent to Purchase Certain Assets of Innovation Neuromonitoring, LLC
Expects to Increase Annual Number of Cases by More than 3,000DENVER, June 26, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp....
Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine
Peer-reviewed publication includes data from the CNM-Au8 Phase 2 RESCUE-ALS trial and its open-label-extension, up to 120 weeks of patient...
Avadel Pharmaceuticals to Host Commercial Day on June 29 for LUMRYZ™ (sodium oxybate) extended release for oral solution, CIII
DUBLIN, Ireland, June 22, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines...
Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’
Media ReleaseCOPENHAGEN, Denmark; June 22, 2023 – Genmab A/S (Nasdaq: GMAB) today announced that epcoritamab, a T-cell engaging bispecific antibody,...
uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
Change in Total Motor Score June 2023 Webcast Presentation Neurofilament Light Chain (Nfl) percentage change from baseline in Cerebrospinal Fluid...
argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis
VYVGART Hytrulo Bottle VYVGART Hytrulo Bottle VYVGART Hytrulo Logo VYVGART Hytrulo Logo Tim Van Hauwermeiren argenx CEO, Tim Van Hauewermeiren...
Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors
Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation Committee Board member Vishal Kapoor...